Skip to content
Technologies

FastPharming

The FastPharming System is iBio’s proprietary plant-based recombinant protein manufacturing platform. It offers a more sustainable method to advance promising candidates from concept to clinic, all the while reducing the time, costs, and scale-up issues associated with traditional mammalian cell culture production.

The Magic Behind the FastPharming System

1 Seeding & Growth N. benthamiana seeds are planted in hydroponic media and transferred to trays for gravity fed loading into LED lit vertical farming racks. Our plants are grown indoors under tightly controlled conditions for consistency & quality. Seedlings are transplanted from germination trays to larger grow trays. Gene Cloning We synthesize the gene, encoding the desired protein and clone it into our high-productivity FastPharming Vectors. Mobilization The gene vectors are then loaded into agrobacteria, which are ideally suited to infect the N. benthamiana plants.
PlantInfiltration We then submerge the plants under a vacuum in a solution containing the agrobacteria to infiltrate the microbes into the leaves, where they then deliver the gene vectors into the plant cells.
ProteinProduction The vectors instruct the plant cells to start producing an abundance of the desired protein, converting each plant into a small factory!
Harvesting After about a week of growth, we harvest the plant leaves and their cargo of recombinant protein.
Purification & Vialing We process the leaves to extract the "green juice," that then undergoes industry standard protein purification before finishing the biologic in its final form. 5

Speed To Clinic

TImeline graph of time required to develop a concept into a GMP substance using Fastpharming gene and protein expression, which is as little as 3 months
Timeline graph of the amount of time required to move from infiltration-ready plants to a drug substance. As little as 14 days, when compared to around 40 days or more with other technologies
  • Rapid Agrobacterium vector availability accelerates the timeline to Master Cell Bank (MCB) generation by as much as 10 months​
  • Bulk drug substance manufacturing timeline reduced because host plants can be ready on-demand thereby eliminating the seed train​
  • Rapid production timeline can support earlier preclinical safety and product stability studies which can potentially further reduce time to IND

 

Time to Drug Substance may vary and does not include product-specific process and assay development work. Mammalian cell culture timelines given above are for illustrative purposes only based upon competitive data from publicly available sources. Actual timelines may vary.

whitepaper pages

White Paper: "Rapid, High-Throughput Screening to Maximize Protein Yields in the FastPharming System®"

How can developers overcome the high costs and long timelines of traditional protein development approaches while maximizing yield? This white paper shares approaches, research data, and specific learnings from Safi Biosolutions’ use case. 
Download White Paper

See the 7 Reasons Why You Should Use Fastpharming to Grow Tomorrow's Biologics

Learn More
Top